Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

CAS Medical Systems Receives FDA Approval To Expand The Labeling For FORE-SIGHT Cerebral Oximeter

CAS Medical Systems, Inc. (CASMED), received US FDA 510(K) approval for expanding the labeling of its FORE-SIGHT Cerebral Oximeter. The new labeling increases the FORE-SIGHT use to the patients, including those with weight less than 2.5 Kilograms.

This Near Infra-Red Spectroscopy (NIRS) based device allows non-invasively and continuously to detect oxygen saturation changes in brain tissue. It will help to quickly act upon to reverse potentially harmful events before they become critical. FORE-SIGHT provides a non-trend, absolute measure of cerebral tissue oxygen saturation for all patient.

We currently use the FORE-SIGHT Cerebral Oximeter for clinical monitoring of term and near-term infants pre-ECMO and or on ECMO, as well as infants with hypoxic-ischemic encephalopathy requiring cooling treatment for neuro-protection. Use of the FORE-SIGHT Cerebral Oximeter for patients below 2.5 kg will allow for clinical monitoring of smaller neonates potentially at risk for intra-ventricular hemorrhage, central apnea, and seizures, commented Dr. K. Rais-Bahrami, Director of the Neonatal-Perinatal Fellowship Program at Children’s National Medical Center in Washington, DC.

Andrew E. Kersey, President and Chief Executive Officer of CASMED, stated: We are pleased with the FDA’s decision to expand clearance for the FORE-SIGHT Cerebral Oximeter to include patients below 2.5 kg. This expanded labeling will allow us additional access into the Neonatal ICU market, where a large percentage of at-risk patients have a low or very low birth weight. In conjunction with the unique benefits that the FORE-SIGHT small sensor offers, including COOL-LIGHT technology that protects fragile skin from heat, non-adhesive sensor solutions, and a very small sensor footprint, the new, expanded labeling uniquely positions CASMED for acceptance in the Neonatal arena.